Explore the complexities of recently found pathomechanisms, cutting-edge research on emergent molecular pathways, and thorough insights into novel treatment options.

The study on the use of subcutaneous racemic ketamine in treatment-resistant depression underscores the significance of a flexible, individualized dosing approach over a 4-week course.

Results from the TRAILBLAZER-ALZ 2 trial highlight the efficacy of donanemab in slowing the progression of early symptomatic Alzheimer disease over a period of 76 weeks.

With expert-led sessions encompassing a broad spectrum of breast disease management, from genetic risk assessment to cutting-edge oncological treatments, the course is a great opportunity to fortify your practice and enhance patient care.

The use of reticulocyte hemoglobin content (CHr) presents a significant advancement in diagnosing iron-deficiency anemia. CHr’s potential in early detection, differentiation of hematologic conditions, and real-time assessment could pave the way for more precise and timely patient care.

Malnutrition is a pressing issue in cancer care, with studies highlighting its significant influence on treatment outcomes and mortality rates. Exploring strategies for prevention, treatment, and ongoing support is vital to improve patient quality of life and success in cancer treatment.